lung

Dutch drug company Lanthio Pharma has granted US-based Tarix Pharmaceuticals an exclusive license to its lanthionine-stabilized Angiotensin-(1-7) agonistic peptide for the treatment of acute lung injury.

Tarix will issue milestone payments and royalties to Lanthio in return for the license. Tarix will also finance further product development.

Lanthio Pharma CEO Bart Wuurman commented, "This deal with Tarix presents an early revenue opportunity and further validates the exciting potential of our technology to discover next generation peptide therapeutics that are more stable and more potent than classical peptides and hence have the characteristics that are required for successful innovative therapeutics."

The agonistic peptide was discovered by Lanthio Pharma, using its proprietary LanthioPep technology.

The compound is stable and resistant to angiotensin-converting enzymes, has high specificity for the MAS receptor, and shows increased intrinsic activity compared to wild-type Angiotensin-(1-7).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Caption: Lanthionine-stabilized Angiotensin-(1-7) is being developed for the treatment of acute lung injury and related indications with high unmet medical need. Credit: renjith krishnan